Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Check out the exclusive pitch deck Valerie Health used to raise $30 million from Redpoint Ventures to automate healthcare faxes - 2Astronauts' brains change shape and position after time in space, study finds
- 3How to watch Dick Clark’s New Year’s Rockin’ Eve with Ryan Seacrest: Start time, TV channel, performers and more
- 4What did the gov’t approve for Israel’s 2026 state budget?
- 5Saucony's $125 'Comfy, Stylish' Sneakers Are Now $55
- ‘We are the alternative’: Anti-Hamas Gaza militia tells BBC group is receiving international support
- Sunken warship found off Danish coast after 225 years in ‘remarkable’ discovery
- NASA’s Artemis II launch leaves Americans in awe: ‘We’re going to the frickin’ moon!’
- Vote in favor of your #1 sort of juice
- Most loved Amusement Park for Small children: Which One Do You Suggest?
- Italian court approves extradition to Germany of Ukrainian suspect in Nord Stream pipeline blast
- Merz: 80% of Syrians in Germany should return in three years
- Hot peppers sent him to the ER. Two years later, a ‘ghost bill’ arrived.
- PA accuses Israel of 'human trafficking' after planeload of Gazans arrives in South Africa
